文献速递认知障碍与痴呆

ApoE4与较低淀粉样蛋白水平下连接介导的tau病理扩散

ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
PubMed 文献 · JAMA Neurol · 2023-01-01

该队列研究纳入ADNI(n=237)和Avid-A05(n=130)两个独立样本,分析ApoE4携带状态、淀粉样蛋白PET与纵向tau PET的关系。结果显示,ApoE4携带者在较低centiloid阈值下即出现淀粉样蛋白相关的tau累积加速,且经早期Braak区域和基于连接性的扩散阶段一致。

要点

  • ApoE4携带者在较低淀粉样蛋白水平下即出现tau累积加速。
  • 淀粉样蛋白PET介导的ApoE4相关tau增加在整体和早期Braak区域均显著。
  • ApoE4状态与淀粉样蛋白PET的交互作用与年度tau PET增加显著相关。

核心结论

  • ApoE4携带者在较低淀粉样蛋白水平下出现淀粉样蛋白相关的tau累积加速,提示ApoE4可能促进淀粉样蛋白驱动的tau在相连脑区更早扩散。

研究设计与样本

  • 队列研究,联合ApoE基因分型、淀粉样蛋白PET和纵向tau PET,来自两个独立样本:ADNI(n=237,2015年4月至2022年8月收集)和Avid-A05(n=130,2013年12月至2017年7月收集)。
  • ADNI为观察性多中心阿尔茨海默病神经影像倡议,Avid-A05为观察性临床试验。
  • ADNI中tau PET平均(SD)随访时间为1.9(0.96)年,Avid-A05为1.4(0.23)年。
  • 参与者为认知正常(ADNI 152例,Avid-A05 77例)或轻度认知障碍(ADNI 107例,Avid-A05 53例),排除ApoE ε2/ε4基因型或痴呆患者。
  • 静息态功能磁共振成像连接模板基于ADNI中42名健康参与者。

主要发现

  • ADNI参与者平均(SD)年龄为73.9(7.35)岁,Avid-A05为70.2(9.7)岁。
  • ADNI中ApoE4携带者107例(45.1%),Avid-A05中45例(34.6%)。
  • 淀粉样蛋白PET介导的ApoE4相关tau PET增加在整体上显著:ADNI b=0.15(95%CI 0.05-0.28,P=.001),Avid-A05 b=0.33(95%CI 0.14-0.54,P<.001)。
  • 在早期Braak区域也发现淀粉样蛋白PET介导的ApoE4相关tau PET增加显著。
  • 经年龄和性别校正后,ApoE4状态与淀粉样蛋白PET的交互作用与年度tau PET增加在早期Braak区域和基于连接性的阶段一致显著相关,ApoE4携带者在较低centiloid阈值下淀粉样蛋白相关tau累积较非携带者加速。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For the Alzheimer disease (AD) therapies to effectively attenuate clinical progression, it may be critical to intervene before the onset of amyloid-associated tau spreading, which drives neurodegeneration and cognitive decline. Time points at which amyloid-associated tau spreading accelerates may depend on individual risk factors, such as apolipoprotein E ε4 (ApoE4) carriership, which is linked to faster disease progression; however, the association of ApoE4 with amyloid-related tau spreading is unclear. OBJECTIVE: To assess if ApoE4 carriers show accelerated amyloid-related tau spreading and propose amyloid positron emission tomography (PET) thresholds at which tau spreading accelerates in ApoE4 carriers vs noncarriers. DESIGN, SETTING, AND PARTICIPANTS: This cohort study including combined ApoE genotyping, amyloid PET, and longitudinal tau PET from 2 independent samples: the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 237; collected from April 2015 to August 2022) and Avid-A05 (n = 130; collected from December 2013 to July 2017) with a mean (SD) tau PET follow-up time of 1.9 (0.96) years in ADNI and 1.4 (0.23) years in Avid-A05. ADNI is an observational multicenter Alzheimer disease neuroimaging initiative and Avid-A05 an observational clinical trial. Participants classified as cognitively normal (152 in ADNI and 77 in Avid-A05) or mildly cognitively impaired (107 in ADNI and 53 in Avid-A05) were selected based on ApoE genotyping, amyloid-PET, and longitudinal tau PET data availability. Participants with ApoE ε2/ε4 genotype or classified as having dementia were excluded. Resting-state functional magnetic resonance imaging connectivity templates were based on 42 healthy participants in ADNI. MAIN OUTCOMES AND MEASURES: Mediation of amyloid PET on the association between ApoE4 status and subsequent tau PET increase through Braak stage regions and interaction between ApoE4 status and amyloid PET with annual tau PET increase through Braak stage regions and connectivity-based spreading stages (tau epicenter connectivity ranked regions). RESULTS: The mean (SD) age was 73.9 (7.35) years among the 237 ADNI participants and 70.2 (9.7) years among the 130 Avid-A05 participants. A total of 107 individuals in ADNI (45.1%) and 45 in Avid-A05 (34.6%) were ApoE4 carriers. Across both samples, we found that higher amyloid PET-mediated ApoE4-related tau PET increased globally (ADNI b, 0.15; 95% CI, 0.05-0.28; P = .001 and Avid-A05 b, 0.33; 95% CI, 0.14-0.54; P < .001) and in earlier Braak regions. Further, we found a significant association between ApoE4 status by amyloid PET interaction and annual tau PET increases consistently through early Braak- and connectivity-based stages where amyloid-related tau accumulation was accelerated in ApoE4carriers vs noncarriers at lower centiloid thresholds, corrected for age and sex. CONCLUSIONS AND RELEVANCE: The findings in this study indicate that amyloid-related tau accumulation was accelerated in ApoE4 carriers at lower amyloid levels, suggesting that ApoE4 may facilitate earlier amyloid-driven tau spreading across connected brain regions. Possible therapeutic implications might be further investigated to determine when best to prevent tau spreading and thus cognitive decline depending on ApoE4 status.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Steward A, Biel D, Dewenter A, et al. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels. JAMA Neurol. 2023. PMID: 37930695. doi:10.1001/jamaneurol.2023.4038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。